The document discusses various statements about treating H. pylori and preventing ulcer relapse. It states that colloidal bismuth subcitrate causes prolonged gastric acid neutralization (A). Eradicating H. pylori with gastric antisecretory drugs provides faster ulcer healing and reduced chance of relapse (D). The anti-H. pylori drugs listed do not include amoxicillin (D). While anti-H. pylori therapy is not indicated for all peptic ulcers (A), resistance develops rapidly to single drugs (B) and acid suppression enhances the regimen's efficacy (C). The preferred regimen to prevent duodenal ulcer relapse is maintenance H2 blocker therapy (
The document discusses various statements about treating H. pylori and preventing ulcer relapse. It states that colloidal bismuth subcitrate causes prolonged gastric acid neutralization (A). Eradicating H. pylori with gastric antisecretory drugs provides faster ulcer healing and reduced chance of relapse (D). The anti-H. pylori drugs listed do not include amoxicillin (D). While anti-H. pylori therapy is not indicated for all peptic ulcers (A), resistance develops rapidly to single drugs (B) and acid suppression enhances the regimen's efficacy (C). The preferred regimen to prevent duodenal ulcer relapse is maintenance H2 blocker therapy (
The document discusses various statements about treating H. pylori and preventing ulcer relapse. It states that colloidal bismuth subcitrate causes prolonged gastric acid neutralization (A). Eradicating H. pylori with gastric antisecretory drugs provides faster ulcer healing and reduced chance of relapse (D). The anti-H. pylori drugs listed do not include amoxicillin (D). While anti-H. pylori therapy is not indicated for all peptic ulcers (A), resistance develops rapidly to single drugs (B) and acid suppression enhances the regimen's efficacy (C). The preferred regimen to prevent duodenal ulcer relapse is maintenance H2 blocker therapy (
The document discusses various statements about treating H. pylori and preventing ulcer relapse. It states that colloidal bismuth subcitrate causes prolonged gastric acid neutralization (A). Eradicating H. pylori with gastric antisecretory drugs provides faster ulcer healing and reduced chance of relapse (D). The anti-H. pylori drugs listed do not include amoxicillin (D). While anti-H. pylori therapy is not indicated for all peptic ulcers (A), resistance develops rapidly to single drugs (B) and acid suppression enhances the regimen's efficacy (C). The preferred regimen to prevent duodenal ulcer relapse is maintenance H2 blocker therapy (
30 Choose the coffect statement about colloidal bismuth
subcitrate: A It causes prolonged neutralization ofgastrtc acid B. It has anti-H.pylori actMty C. It relieves peptic ulcer pain promptly D. All of the above are correct (p. 597) 44.31 Eradication of H.pylori along with gastric antisecre- tory drugs affords the following benefit(s): A Faster relief of ulcer pain B. Faster ulcer healing C. Reduced chance of ulcer relapse D. Both 'B' and 'C' are correct (p. 597) 44.32 The drugs employed for anti-H.pylori therapy include the following except: A Ciprofloxacin B. Clarithromycin C. Tinidazole D. Amoxicillin (p. 597, 598) 44.33 The following is true of anti-H.pylori therapy except: A It is indicated in all patients of peptic ulcer B. Resistance to any single antimicrobial drug develops rapidly C. Concurrent suppression of gastric acid enhances efficacy of the regimen D. Colloidal bismuth directly inhibits H.pylori but has poor patient acceptability (p. 598)
I 44.34 The preferred regimen for preventing duodenal ulcer
relapse is: A Maintenance antacid regimen B . Maintenance H 2 blocker regimen C. On demand intermittent H2 blocker regimen D. Maintenance sucralfate regimen (p. 598) 144.30B 44.31D 44.32A 44.33A 44.34B I